JPMorgan Chase & Co. Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price objective upped by JPMorgan Chase & Co. from $33.00 to $38.00 in a research note released on Thursday,Benzinga reports. The firm currently has an overweight rating on the stock.

Other analysts also recently issued research reports about the stock. StockNews.com raised shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, November 15th. Citigroup lifted their price objective on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, November 19th. The Goldman Sachs Group lifted their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. HC Wainwright increased their price objective on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the stock a “buy” rating in a research note on Monday, November 18th. Finally, Bank of America increased their price target on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.64.

Syndax Pharmaceuticals Stock Up 3.1 %

Shares of SNDX stock opened at $16.09 on Thursday. The company’s fifty day simple moving average is $18.60 and its two-hundred day simple moving average is $19.98. Syndax Pharmaceuticals has a 52 week low of $15.00 and a 52 week high of $25.34. The stock has a market cap of $1.37 billion, a P/E ratio of -4.43 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $9.16 million. During the same period in the previous year, the business earned ($0.73) earnings per share. On average, analysts anticipate that Syndax Pharmaceuticals will post -3.69 EPS for the current fiscal year.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of Syndax Pharmaceuticals by 13.6% during the 1st quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company’s stock worth $117,262,000 after purchasing an additional 591,631 shares during the period. State Street Corp grew its position in Syndax Pharmaceuticals by 4.1% in the third quarter. State Street Corp now owns 3,770,826 shares of the company’s stock worth $72,588,000 after acquiring an additional 148,491 shares during the period. Sofinnova Investments Inc. boosted its position in shares of Syndax Pharmaceuticals by 33.9% during the 2nd quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company’s stock worth $44,215,000 after purchasing an additional 545,129 shares during the period. Geode Capital Management LLC lifted its stake in Syndax Pharmaceuticals by 3.5% during the third quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company’s stock worth $38,066,000 after purchasing an additional 66,459 shares in the last quarter. Finally, First Turn Management LLC grew its holdings in shares of Syndax Pharmaceuticals by 85.4% in the third quarter. First Turn Management LLC now owns 1,187,165 shares of the company’s stock valued at $22,853,000 after purchasing an additional 546,776 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).